{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T15:18:36Z","timestamp":1771600716087,"version":"3.50.1"},"reference-count":32,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003417","name":"German Social Accident Insurance","doi-asserted-by":"crossref","award":["FP 295"],"award-info":[{"award-number":["FP 295"]}],"id":[{"id":"10.13039\/501100003417","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,10,15]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Calretinin and mesothelin are molecular markers for the detection of malignant mesothelioma at early stages. Our objective was the re-evaluation of factors influencing calretinin and mesothelin concentrations in plasma of cancer-free men in order to minimise false-positive tests when using commercial assays approved for clinical diagnostics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>This re-evaluation used data and archived blood samples of the population-based Heinz Nixdorf Recall Study (HNRS) collected from 2011 to 2014.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>The present analysis comprised of 569 cancer-free men at the time of blood sampling (median age 70 years) from HNRS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcomes<\/jats:title>\n                    <jats:p>Mesothelin plasma concentration was determined using ELISA and CLEIA (chemiluminescent enzyme immunoassay). Calretinin plasma concentration was assessed using ELISA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with the previous determination of concentrations, we detected less false-positive tests using the commercial assays. In this analysis, we found nine false-positive calretinin tests using the ELISA (specificity 98.4%, 95%\u2009CI 97.0% to 99.2%) and 24 false-positive mesothelin tests using both ELISA and CLEIA (specificity 95.8%, 95%\u2009CI 93.8% to 97.2%). We confirmed renal dysfunction as major predictor of elevated marker concentrations. Mesothelin was additionally affected by bronchitis. Furthermore, elevated inflammation values and hypertension only affected the mesothelin concentration determined by ELISA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The newly available assays of calretinin and mesothelin approved for clinical diagnostics showed high specificities in the population-based cohort of elderly men without a malignant disease. The current evaluation provides a basis to consider influencing factors in order to further improve the diagnostic procedure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-039079","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T11:37:01Z","timestamp":1613648221000},"page":"e039079","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Re-evaluation of potential predictors of calretinin and mesothelin in a population-based cohort study using assays for the routine application in clinical medicine"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0148-8859","authenticated-orcid":false,"given":"Swaantje","family":"Casjens","sequence":"first","affiliation":[{"name":"Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Johnen","sequence":"additional","affiliation":[{"name":"Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Raiko","sequence":"additional","affiliation":[{"name":"Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Pesch","sequence":"additional","affiliation":[{"name":"Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Taeger","sequence":"additional","affiliation":[{"name":"Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"T\u00f6pfer","sequence":"additional","affiliation":[{"name":"Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Schonefeld","sequence":"additional","affiliation":[{"name":"Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Moebus","sequence":"additional","affiliation":[{"name":"Institute of Medical Informatics, Biometry and Epidemiology, University Duisburg-Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl-Heinz","family":"J\u00f6ckel","sequence":"additional","affiliation":[{"name":"Institute of Medical Informatics, Biometry and Epidemiology, University Duisburg-Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Br\u00fcning","sequence":"additional","affiliation":[{"name":"Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Weber","sequence":"additional","affiliation":[{"name":"Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"key":"2025121221230263000_11.2.e039079.1","doi-asserted-by":"publisher","DOI":"10.1136\/oemed-2017-104298"},{"key":"2025121221230263000_11.2.e039079.2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bjc.6602307","article-title":"The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050","volume":"92","author":"Hodgson","year":"2005","journal-title":"Br J Cancer"},{"key":"2025121221230263000_11.2.e039079.3","first-page":"1164","article-title":"Malignant pleural mesothelioma: factors influencing the prognosis","volume":"26","author":"Mineo","year":"2012","journal-title":"Oncology"},{"key":"2025121221230263000_11.2.e039079.4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev-med-041316-085813","article-title":"New concepts in the treatment of malignant pleural mesothelioma","volume":"69","author":"Wald","year":"2018","journal-title":"Annu Rev Med"},{"key":"2025121221230263000_11.2.e039079.5","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3375-5","article-title":"Calretinin as a blood-based biomarker for mesothelioma","volume":"17","author":"Johnen","year":"2017","journal-title":"BMC Cancer"},{"key":"2025121221230263000_11.2.e039079.6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004145"},{"key":"2025121221230263000_11.2.e039079.7","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0063-2016"},{"key":"2025121221230263000_11.2.e039079.8","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-32315-3","article-title":"Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers","volume":"8","author":"Johnen","year":"2018","journal-title":"Sci Rep"},{"key":"2025121221230263000_11.2.e039079.9","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.bbapap.2013.12.007","article-title":"Biomarker research with prospective study designs for the early detection of cancer","volume":"1844","author":"Pesch","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"2025121221230263000_11.2.e039079.10","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2006.079327"},{"key":"2025121221230263000_11.2.e039079.11","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2008.121913"},{"key":"2025121221230263000_11.2.e039079.12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/BMI.S3927","article-title":"Assessment of confounding factors affecting the tumor markers SMRP, CA125, and CYFRA21-1 in serum","volume":"5","author":"Weber","year":"2010","journal-title":"Biomark Insights"},{"key":"2025121221230263000_11.2.e039079.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017104","article-title":"Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study","volume":"7","author":"Casjens","year":"2017","journal-title":"BMJ Open"},{"key":"2025121221230263000_11.2.e039079.14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.neuro.2016.11.005","article-title":"Associations between former exposure to manganese and olfaction in an elderly population: results from the heinz Nixdorf recall study","volume":"58","author":"Casjens","year":"2017","journal-title":"Neurotoxicology"},{"key":"2025121221230263000_11.2.e039079.15","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.123579"},{"key":"2025121221230263000_11.2.e039079.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1697-1"},{"key":"2025121221230263000_11.2.e039079.17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-242"},{"key":"2025121221230263000_11.2.e039079.18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.20.11531"},{"key":"2025121221230263000_11.2.e039079.19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013324"},{"key":"2025121221230263000_11.2.e039079.20","first-page":"97","article-title":"Incidence of malignant mesothelioma in Germany 2009-2013","volume":"28","author":"Lehnert","year":"2017","journal-title":"Cancer Causes Control"},{"key":"2025121221230263000_11.2.e039079.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2004.09.025"},{"key":"2025121221230263000_11.2.e039079.22","doi-asserted-by":"publisher","DOI":"10.3109\/1354750X.2010.482214"},{"key":"2025121221230263000_11.2.e039079.23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20143581","article-title":"Bnp as a major player in the Heart-Kidney connection","volume":"20","author":"Okamoto","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025121221230263000_11.2.e039079.24","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/resp.13788","article-title":"Malignant mesothelioma cells secrete natriuretic peptides: data and diagnostic clinical implications","volume":"25","author":"Tsolaki","year":"2020","journal-title":"Respirology"},{"key":"2025121221230263000_11.2.e039079.25","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/HJH.0000000000001151","article-title":"The incidence of hypertension and its risk factors in the German adult population: results from the German National health interview and examination survey 1998 and the German health interview and examination survey for adults 2008-2011","volume":"35","author":"Diederichs","year":"2017","journal-title":"J Hypertens"},{"key":"2025121221230263000_11.2.e039079.26","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00408-019-00244-1","article-title":"Mesothelin, calretinin, and megakaryocyte potentiating factor as biomarkers of malignant pleural mesothelioma","volume":"197","author":"Jim\u00e9nez-Ram\u00edrez","year":"2019","journal-title":"Lung"},{"key":"2025121221230263000_11.2.e039079.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2007.07.042"},{"key":"2025121221230263000_11.2.e039079.28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3233\/CBM-2007-3602","article-title":"Soluble mesothelin-related peptides (SMRP) - high stability of a potential tumor marker for mesothelioma","volume":"3","author":"Weber","year":"2007","journal-title":"Cancer Biomark"},{"key":"2025121221230263000_11.2.e039079.29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00420-013-0853-1","article-title":"Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers","volume":"87","author":"Felten","year":"2014","journal-title":"Int Arch Occup Environ Health"},{"key":"2025121221230263000_11.2.e039079.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14794-0"},{"key":"2025121221230263000_11.2.e039079.31","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200811-1729OC"},{"key":"2025121221230263000_11.2.e039079.32","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.21037\/jtd.2017.12.17","article-title":"Biomarkers in the prevention and follow-up of workers exposed to asbestos","volume":"10","author":"Foddis","year":"2018","journal-title":"J Thorac Dis"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-039079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T05:23:11Z","timestamp":1765603391000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-039079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,18]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/bmjopen-2020-039079"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-039079","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}